Highest-materiality recent filing
Skye Bioscience stockholders approve 3x increase in authorized common shares to 300M
Charter Amendment increases authorized common shares from 100M to 300M, filed with Nevada on May 28, 2026.
Skye Bioscience receives Nasdaq delisting notice for failing minimum stockholders' equity
Stockholders' equity was $9,011,804, below Nasdaq Global Market's $10M minimum requirement.
Skye Bioscience amends 8-K to correct option repricing share count to 2,458,158
Amendment corrects a scrivener's error: total shares underlying Repriced Options is 2,458,158.
Skye Bioscience appoints John Sharp as CFO and reprices underwater options to $0.6150
John P. Sharp appointed CFO effective March 31, 2026; services via Lohman & Associates at $25,600/month for up to 64 hours.
Skye Bioscience receives Nasdaq deficiency notice for bid price below $1.00
Received deficiency letter on March 17, 2026 for failure to maintain $1.00 minimum bid price for 30 consecutive business days.
Net loss Q4 2025: $14.4M; full year $55.9M; cash & equivalents $25.7M as of Dec 31, 2025.
CFO Kaitlyn Arsenault to step down Feb 20; CEO Punit Dhillon appointed principal accounting officer
CFO Kaitlyn Arsenault departs Feb 20, 2026; no disagreement with auditors or company on financials.
Nimacimab 200mg + semaglutide 2.4mg achieved 22.3% mean weight loss at 52 weeks; no plateau observed, suggesting further efficacy potential.
Skye Bioscience licenses Halozyme's ENHANZE technology for subcutaneous nimacimab
Non-exclusive license to Halozyme's ENHANZE drug delivery tech for subcutaneous nimacimab formulation.
Nimacimab plus semaglutide achieved 29% relative increase in weight loss vs semaglutide alone at 26 weeks; clean safety profile.
Nimacimab monotherapy at 200 mg failed primary endpoint with placebo-subtracted weight loss of -1.26% (p=0.2699, mITT).
Skye Bioscience Q2 net loss $17.6M; Phase 2a top-line data due late Q3/early Q4 2025
Net loss of $17.6M for Q2 2025, vs $7.9M in Q2 2024; R&D expense rose to $14.3M from $4.1M.
Skye Bioscience changes auditor to CBIZ CPAs; shareholders re-elect board at annual meeting
Marcum LLP resigned as auditor June 9, 2025 after acquisition by CBIZ; CBIZ CPAs engaged for FY 2025.
Skye Bioscience Q1 net loss $11.1M; nimacimab combo shows >30% weight loss in preclinical
Net loss for Q1 2025 was $11.1M ($2.2M non-cash share-based comp) vs $5.0M in Q1 2024.
Skye Bioscience Q4 net loss $9.7M; Phase 2a obesity trial top-line data accelerated to late Q3 2025
Cash $68.4M at Dec 31, 2024; projected runway through at least Q1 2027.
Amendment gives administrator broader authority to cancel, assume, accelerate, or cash out outstanding awards upon a Change in Control.
Skye Bioscience Q3 net loss $3.9M; cash $76.5M; nimacimab Phase 2 enrolling, interim data Q2 2025
Net loss $3.9M in Q3 2024 vs $24.9M loss in Q3 2023; decrease driven by absence of $21.2M in-process R&D acquisition expense.
Skye Bioscience appoints Paul Grayson as Chairman; CEO Dhillon gets salary hike and stock options
Paul Grayson appointed Chairman effective Oct 25, 2024; CEO Punit Dhillon resigns as Chairman, remains on Board.
Skye Bioscience stockholders approve amended omnibus incentive plan, increasing share pool by 1.54M
Stockholders voted 17.4M for, 6.2M against to approve the Amended and Restated Omnibus Incentive Plan.
Skye Bioscience appoints Puneet Arora as Chief Medical Officer, grants 225,000 stock options
Puneet S. Arora, MD, appointed CMO effective Sept 3, 2024; base salary $475k with 40% target bonus.
Skye Bioscience appoints Dr. Karen Smith to board; two directors resign effective Aug 1
Appoints Dr. Karen Smith MD, PhD, MBA, LLM to board; retainer $40k/yr plus committee fees and 40,000-share option.
Phase 2a trial of SBI-100 in 56 patients with POAG or OHT did not meet primary IOP endpoint vs placebo.
Skye Bioscience reports pro forma equity >$5M after $90M private placement
Closed private placement of 15.7M shares and 10.0M pre-funded warrants for $90M gross ($83.5M net).
Skye Bioscience raises $40M via PIPE of 4M shares at $10 each
Issued 4,000,000 shares at $10.00 per share for gross proceeds of $40,000,000.
Skye Bioscience appoints Dr. Annalisa Jenkins to board; director Dalesandro to resign Aug 1
Dr. Annalisa Jenkins appointed to board effective Feb 29, 2024, filling newly created eighth seat.
Skye Bioscience raises $46.2M, sells real estate; equity now $49M for Nasdaq compliance
Net proceeds of ~$46.2M from private placement of 11.7M shares and pre-funded warrants on Jan 31, 2024.
Skye Bioscience raises $50.25M in PIPE led by 5AM Ventures; funds obesity Phase 2 trial
Private placement of 11.8M shares at $2.305 and pre-funded warrants for 9.98M shares at $2.3049.
Skye licenses SBI-100 to Tautomer for Africa, terminates UM 8930 license, sells Canadian lab
Exclusive license to Tautomer for SBI-100 (THC prodrug) suppository in Africa for chronic pain and other indications.
Skye Bioscience increases authorized common shares from 20M to 100M
Filed Certificate of Amendment on Nov 6, 2023, raising authorized common shares from 20,000,000 to 100,000,000.
On September 3, 2024, Skye Bioscience, Inc. (the “Company”) announced the appointment of Puneet S. Arora, MD, MS, FACE, as Chief Medical Officer, effective as of September 3, 2024 (the “Effective Date”).
On July 1, 2024, each of Keith Ward, PhD and Praveen Tyle, PhD informed the Board of their intent to resign as a member of the Board, effective August 1, 2024.
the Board approved an increase in its authorized size from eight to nine members and appointed Karen L. Smith MD, PhD, MBA, LLM to fill the vacancy created by such increase.
On July 1, 2024, each of Keith Ward, PhD and Praveen Tyle, PhD informed the Board of their intent to resign as a member of the Board, effective August 1, 2024.
Margaret Dalesandro, Ph.D. informed the Board of her intent to resign as a member of the Board, effective August 1, 2024.
appointed Annalisa Jenkins, M.B.B.S., F.R.C.P. to fill the vacancy created by such increase.
Max materiality 0.85 · Median 0.65 · Most common event other_material